一二三四区视频,亚洲少妇熟女色,日本久热无码视频网,欧美国产日韩大尺度,亚洲a视频,久久少妇一区二区,日韩999无码视频,刺激久久久久久久,啊啊啊啊不要啊在线

Welcome to chemicalbook!
+1 (818) 612-2111
RFQ
Try our best to find the right business for you.
Do not miss inquiry messages Please log in to view all inquiry messages.

Welcome back!

RFQ
skype
MY Account
Top
Postion:Product Catalog >Biochemical Engineering>Inhibitors>Mitogen-activated protein kinase (MAPK)>Raf inhibitors>PLX-4720
PLX-4720
  • PLX-4720

PLX-4720 NEW

Price $48 $101
Package 10mg 50mg
Supply Ability: 10g
Update Time: 2026-07-08

Product Details

Product Name: PLX-4720 CAS No.: 918505-84-7
Purity: 99.93% Supply Ability: 10g
Release date: 2026/07/08

Product Introduction

Bioactivity

NamePLX-4720
DescriptionPLX-4720 is a potent and selective B-Raf (V600E) inhibitor designed to block the ATP-binding site of oncogenic B-Raf with IC50 of 13 nM.
Cell ResearchCells are treated with various concentrations PLX-4720 for 24, 48, and 72 hours. Cell proliferation is measured by using the CellTiter-Glo Luminescent Cell Viability Assay or MTT assay. For cell cycle analysis, supernatant and cells are collected, pelleted, and fixed with 70% ethanol. Before staining with propidium iodide (10 μg/mL), cells are incubated for 1 hour at 37 °C in 0.5 mg/mL RNase I to rid samples of residual RNA contamination. Samples are then analyzed by using the EPICS XL apparatus. For the assessment of apoptosis, media and cells are harvested and pelleted before staining with annexin-FITC and propidium iodide. Samples are subsequently analyzed by using the EPICS XL apparatus [1].
Kinase AssayIn vitro Raf kinase activities: The in vitro kinase activities of wild type Raf and mutants are determined by measuring phosphorylation of biotinylated-MEK protein using Perkin-Elmer's AlphaScreen Technology. For each enzyme (0.1 ng), 20-μL reactions are carried out in 20 mM Hepes (pH 7.0), 10 mM MgCl2, 1 mM DTT, 0.01% Tween-20, 100 nM biotin-MEK protein, various ATP concentrations, and increasing concentrations of PLX-4720 at room temperature. Reactions are stopped at 2, 5, 8, 10, 20, and 30 minutes with 5 μL of a solution containing 20 mM Hepes (pH 7.0), 200 mM NaCl, 80 mM EDTA, and 0.3% BSA. The stop solution also includes phospho-MEK Antibody, Streptavidin-coated Donor beads and Protein A Acceptor beads. The antibody and beads are preincubated in stop solution in the dark at room temperature for 30 minutes. The final dilution of antibody is 1/2,000, and the final concentration of each bead is 10 μg/mL. The assay plates are incubated at room temperature for one hour then are read on a PerkinElmer AlphaQuest reader [1].
Animal ResearchFemale athymic mice (NCr nu/nu) were implanted s.c. on day 0 with 30–60 mg COLO205 tumor fragments. Treatments began on day 11, when the mean estimated tumor mass was 104 mg (range, 95–113 mg). All animals were dosed with vehicle (5% DMSO, 1% methylcellulose) or PLX4720 suspended in vehicle by gavage daily for 14 consecutive days. Tumor burden (mg) was estimated from caliper measurements [1].
In vitroMETHODS: 1205Lu and C8161 cells were treated with PLX4720 (0.1, 1, 10 μM, 24 hours) and stained with Annexin V/FITC and propidium iodide (PI) to analyze cell apoptosis. RESULTS PLX4720 induced cell cycle arrest and apoptosis in 1205Lu cells in a concentration-dependent manner. [1] METHODS: After 8505c, TPC-1 and NT cells were treated with PLX4720 (1μM or 10μM) for 72 hours, bromodeoxyuridine (BrdU, 10μM) was added for 1 hour, followed by cell cycle analysis, BrdU assay and apoptosis assay. RESULTS Treatment of 8505c cells with 1 μM PLX4720 resulted in a >90% reduction in phosphorylated ERK-1/ERK-2 protein levels after 1 hour; there was no significant difference in cell proliferation even after 72 hours, whereas treatment of 8505c cells with 10 μM PLX4720 Cells reduced phosphorylated ERK-1/ERK-2 BrdU uptake for 1 hour or 72 hours; in TPC-1 cells, treatment with 1 μM PLX4720 for 1 hour resulted in increased phosphorylated ERK-1/ERK-2 protein levels ( About 80%); PLX4720 phosphorylated ERK-1/ERK-2 decreased by about 45% after treatment with 10 μM for 1 hour; both 1 μM and 10 μM PLX4720 caused lower cell proliferation; only 10 μM PLX4720 decreased after 72 hours of treatment The migration of TPC-1 cells was inhibited; NT cells treated with 10 μM PLX4720 showed significantly reduced cell proliferation. [3]
In vivoMETHODS: Nude mice bearing BRAF COLO205 cells (BRAFV600E series mutation) were treated with PLX4720 (5, 20, 1000 mg/kg, once daily, orally) and tumor growth in the mice was observed. RESULTS The lower dose of 5 mg/kg PLX4720 had very limited effect on tumor growth; 20 mg/kg PLX4720 treatment of tumor-bearing mice resulted in a substantial block in tumor growth; PLX4720 treatment was well tolerated, and increasing the PLX4720 dose to 1,000 mg/kg resulted in increased plasma levels (up to 600 μM) without any evidence of adverse reactions. [1]
StoragePowder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature.
Solubility InformationEthanol : < 1 mg/mL (insoluble or slightly soluble)
DMSO : 247 mg/mL (596.86 mM), Sonication is recommended.
10% DMSO+40% PEG300+5% Tween 80+45% Saline : 5 mg/mL (12.08 mM), Sonication is recommended.
H2O : < 1 mg/mL (insoluble or slightly soluble)
KeywordsRaf kinases | Raf | PLX-4720 | PLX 4720 | Inhibitor | inhibit | C-Raf-1 (Y340D/Y341D) | B-Raf (V600E) | B-Raf
Inhibitors RelatedRegorafenib monohydrate | Exarafenib | Doramapimod | Vemurafenib | Sulindac sulfide | Sorafenib | Regorafenib | Dabrafenib | Dabrafenib Mesylate | LY3009120 | GW 441756 | RMC-7977
Related Compound LibrariesTarget-Focused Phenotypic Screening Library | Bioactive Compound Library | Pain-Related Compound Library | Anti-Neurodegenerative Disease Compound Library | Membrane Protein-targeted Compound Library | HIF-1 Signaling Pathway Compound Library | Kinase Inhibitor Library | Inhibitor Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | Anti-COVID-19 Compound Library | Anti-Cancer Active Compound Library

Company Profile Introduction

Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers. TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.

You may like

Recommended supplier

Product name Price   Suppliers Update time
$1.10
VIP6Y
Dideu Industries Group Limited
2025-11-18
$15.00
Zhuozhou Wenxi import and Export Co., Ltd
2021-07-02
$1.00
VIP8Y
Career Henan Chemical Co
2019-07-06
$1.00
VIP8Y
Career Henan Chemical Co
2019-07-06

TargetMol Chemicals Inc.

6YR United StatesUnited States
  • Since: 2011-01-07
  • Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY
合山市| 绩溪县| 军事| 保靖县| 远安县| 乌拉特前旗| 腾冲县| 普兰县| 蒙山县| 嘉鱼县| 资中县| 商城县| 昭苏县| 边坝县| 常熟市| 新密市| 道真| 通许县| 济南市| 司法| 陆丰市| 尉犁县| 米易县| 响水县| 周宁县| 通江县| 巫溪县| 米林县| 汶川县| 龙游县| 洪江市| 壤塘县| 平乐县| 武鸣县| 双流县| 介休市| 延津县| 七台河市| 建湖县| 江门市| 卢氏县|